# Apoptosis in Cardiac Conditions Including Cirrhotic Cardiomyopathy

**Authors:** Fengxue Yu, Dae Gon Ryu, Ki Tae Yoon, Hongqun Liu, Samuel S. Lee

PMC · DOI: 10.3390/ijms26136423 · International Journal of Molecular Sciences · 2025-07-03

## TL;DR

This review discusses how programmed cell death (apoptosis) contributes to heart diseases, including cirrhotic cardiomyopathy, and explores potential anti-apoptotic treatments.

## Contribution

The paper reviews apoptotic mechanisms in cardiac diseases and highlights the potential of anti-apoptotic therapies for cirrhotic cardiomyopathy.

## Key findings

- Apoptosis contributes to cardiac dysfunction in conditions like heart failure and cirrhotic cardiomyopathy.
- Current treatments for non-cirrhotic heart failure are not suitable for cirrhotic patients due to peripheral vasodilatation.
- Anti-apoptotic therapies may offer new treatment options for cirrhotic cardiomyopathy.

## Abstract

Apoptosis is a highly regulated process of programmed cell death and plays a crucial pathogenic role in a variety of conditions including cardiovascular diseases. There are two pathways leading to apoptosis, the intrinsic and extrinsic pathways. In the intrinsic pathway, also known as the mitochondria-mediated pathway, the cell kills itself because it senses cell stress. Mitochondria account for 30% of cardiomyocyte volume, and therefore, the heart is vulnerable to apoptosis. The extrinsic pathway, also known as the death receptor-mediated pathway, is initiated by death receptors, members of the tumor necrosis factor receptor gene superfamily. Excessive apoptosis is involved in cardiac dysfunction in different cardiac conditions, including heart failure, ischemic heart disease, and cirrhotic cardiomyopathy. The last entity is a serious cardiac complication of patients with cirrhosis. To date, there is no effective treatment for cirrhotic cardiomyopathy. The conventional treatments for non-cirrhotic heart failure such as vasodilators are not applicable due to the generalized peripheral vasodilatation in cirrhotic patients. Exploring new approaches for the treatment of cirrhotic cardiomyopathy is therefore of utmost importance. Since apoptosis plays an essential role in the pathogenesis and progression of cardiovascular conditions, anti-apoptotic treatment could potentially prevent/attenuate the development and progression of cardiac diseases. Anti-apoptotic treatment may also apply to cirrhotic cardiomyopathy. The present review summarizes apoptotic mechanisms in different cardiac diseases, including cirrhotic cardiomyopathy, and potential therapies to regulate apoptosis in these conditions.

## Linked entities

- **Diseases:** heart failure (MONDO:0005252), ischemic heart disease (MONDO:0024644), cirrhotic cardiomyopathy (MONDO:0018932)

## Full-text entities

- **Diseases:** Cirrhotic Cardiomyopathy (MESH:D009202), cardiovascular diseases (MESH:D002318), cirrhotic (MESH:D000094724), ischemic heart disease (MESH:D017202), cirrhosis (MESH:D005355), Cardiac Conditions (MESH:D006331), heart failure (MESH:D006333)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12249617/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12249617/full.md

## References

76 references — full list in the complete paper: https://tomesphere.com/paper/PMC12249617/full.md

---
Source: https://tomesphere.com/paper/PMC12249617